Bellerophon Therapeutics, Inc.
BLPH
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 5.64M | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 5.64M | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | 5.64M | -- | -- |
| SG&A Expenses | 1.63M | 2.36M | 1.61M | 1.37M | 1.37M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.17M | 5.26M | 4.16M | 5.09M | 5.12M |
| Operating Income | -2.17M | -5.26M | 1.48M | -5.09M | -5.12M |
| Income Before Tax | -1.92M | -5.14M | 1.55M | -5.02M | -5.07M |
| Income Tax Expenses | -- | -- | -1.28M | 0.00 | -- |
| Earnings from Continuing Operations | -1.92M | -5.14M | 2.82M | -5.02M | -5.07M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.92M | -5.14M | 2.82M | -5.02M | -5.07M |
| EBIT | -2.17M | -5.26M | 1.48M | -5.09M | -5.12M |
| EBITDA | -2.17M | -5.26M | 1.48M | -5.08M | -5.10M |
| EPS Basic | -0.16 | -0.42 | 0.27 | -0.52 | -0.53 |
| Normalized Basic EPS | -0.11 | -0.26 | 0.09 | -0.33 | -0.33 |
| EPS Diluted | -0.16 | -0.42 | 0.27 | -0.53 | -0.53 |
| Normalized Diluted EPS | -0.11 | -0.26 | 0.09 | -0.33 | -0.33 |
| Average Basic Shares Outstanding | 12.23M | 12.23M | 10.36M | 9.57M | 9.55M |
| Average Diluted Shares Outstanding | 12.23M | 12.23M | 10.61M | 9.57M | 9.55M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
